Staphylococcus aureus metabolic adaptations during the transition from a daptomycin susceptibility phenotype to a daptomycin nonsusceptibility phenotype

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 7, 2015, Pages 4226-4238

  Gaupp, Rosmarie ^a,b   Lei, Shulei ^a   Reed, Joseph M ^a   Peisker, Henrik ^b   Boyle Vavra, Susan ^c   Bayer, Arnold S ^d   Bischoff, Markus ^b   Herrmann, Mathias ^b   Daum, Robert S ^c   Powers, Robert ^a   Somerville, Greg A ^a  

^a UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^b SAARLAND UNIVERSITY   (Germany)

^c UNIVERSITY OF CHICAGO   (United States)

^d HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON; DAPTOMYCIN; PEPTIDOGLYCAN; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; TEICHOIC ACID; ACONITATE HYDRATASE; AMINO ACID; ANTIINFECTIVE AGENT;

ADAPTATION; AMINO ACID METABOLISM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL METABOLISM; CITRIC ACID CYCLE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PURINE SYNTHESIS; PYRIMIDINE SYNTHESIS; STAPHYLOCOCCUS AUREUS; CELL WALL; CHEMISTRY; DRUG EFFECTS; GENETICS; METABOLISM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TEST; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

ACONITATE HYDRATASE; AMINO ACIDS; ANTI-BACTERIAL AGENTS; CELL WALL; CITRIC ACID CYCLE; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; MAGNETIC RESONANCE SPECTROSCOPY; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PEPTIDOGLYCAN; PHENOTYPE; PURINES; PYRIMIDINES; STAPHYLOCOCCUS AUREUS; TEICHOIC ACIDS; VANCOMYCIN RESISTANCE;

EID: 84931274795     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00160-15     Document Type: Article

References (82)

1. Sakoulas G, Eliopoulos GM, Alder J, Eliopoulos CT. 2003. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 47:1714-1718. http://dx.doi.org/10.1128/AAC.47.5.1714-1718.2003.
2. Wootton M, MacGowan AP, Walsh TR. 2006. Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA isolates. Antimicrob Agents Chemother 50:4195-4197. http://dx.doi.org/10 .1128/AAC.00678-06.
3. Fowler VG, Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fätkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE. 2006. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355:653-665. http://dx.doi.org/10.1056/NEJMoa053783.
4. Falagas ME, Giannopoulou KP, Ntziora F, Vardakas KZ. 2007. Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence. J Antimicrob Chemother 60:7-19. http://dx.doi.org/10.1093/jac/dkm137.
5. Steenbergen JN, Alder J, Thorne GM, Tally FP. 2005. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 55:283-288. http://dx.doi.org/10.1093/jac /dkh546.
6. Hayden MK, Rezai K, Hayes RA, Lolans K, Quinn JP, Weinstein RA. 2005. Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 43:5285-5287. http://dx .doi.org/10.1128/JCM.43.10.5285-5287.2005.
7. Mangili A, Bica I, Snydman DR, Hamer DH. 2005. Daptomycinresistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 40:1058-1060. http://dx.doi.org/10.1086/428616.
8. Marty FM, Yeh WW, Wennersten CB, Venkataraman L, Albano E, Alyea EP, Gold HS, Baden LR, Pillai SK. 2006. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol 44:595-597. http://dx.doi.org/10.1128/JCM.44.2.595-597.2006.
9. Skiest DJ. 2006. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 44:655-656. http://dx.doi .org/10.1128/JCM.44.2.655-656.2006.
10. Julian K, Kosowska-Shick K, Whitener C, Roos M, Labischinski H, Rubio A, Parent L, Ednie L, Koeth L, Bogdanovich T, Appelbaum PC. 2007. Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis. Antimicrob Agents Chemother 51:3445-3448. http://dx.doi.org/10.1128 /AAC.00559-07.
11. Vikram HR, Havill NL, Koeth LM, Boyce JM. 2005. Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin. J Clin Microbiol 43: 5384-5387. http://dx.doi.org/10.1128/JCM.43.10.5384-5387.2005.
12. Kirby A, Mohandas K, Broughton C, Neal TJ, Smith GW, Pai P, Nistal de Paz C. 2009. In vivo development of heterogeneous glycopeptide-intermediate Staphylococcus aureus (hGISA), GISA and daptomycin resistance in a patient with meticillin-resistant S. aureus endocarditis. J Med Microbiol 58:376-380. http://dx.doi.org/10.1099/jmm.0.006486-0.
13. Murthy MH, Olson ME, Wickert RW, Fey PD, Jalali Z. 2008. Daptomycin non-susceptible meticillin-resistant Staphylococcus aureus U S A 300 isolate. J Med Microbiol 57:1036-1038. http://dx.doi.org/10.1099 /jmm.0.2008/000588-0.
14. Sakoulas G, Brown J, Lamp KC, Friedrich LV, Lindfield KC. 2009. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience. Clin Ther 31:1936-1945. http://dx.doi .org/10.1016/j.clinthera.2009.09.012.
15. Silverman JA, Perlmutter NG, Shapiro HM. 2003. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 47:2538-2544. http://dx .doi.org/10.1128/AAC.47.8.2538-2544.2003.
16. Pogliano J, Pogliano N, Silverman JA. 2012. Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins. J Bacteriol 194:4494-4504. http://dx.doi.org/10 .1128/JB.00011-12.
17. Kuroda M, Kuroda H, Oshima T, Takeuchi F, Mori H, Hiramatsu K. 2003. Two-component system VraSR positively modulates the regulation of cell-wall biosynthesis pathway in Staphylococcus aureus. Mol Microbiol 49:807-821. http://dx.doi.org/10.1046/j.1365-2958.2003.03599.x.
18. Muthaiyan A, Silverman JA, Jayaswal RK, Wilkinson BJ. 2008. Transcriptional profiling reveals that daptomycin induces the Staphylococcus aureus cell wall stress stimulon and genes responsive to membrane depolarization. Antimicrob Agents Chemother 52:980-990. http://dx.doi.org /10.1128/AAC.01121-07.
19. Dengler V, Meier PS, Heusser R, Berger-Bächi B, McCallum N. 2011. Induction kinetics of the Staphylococcus aureus cell wall stress stimulon in response to different cell wall active antibiotics. BMC Microbiol 11:16. http://dx.doi.org/10.1186/1471-2180-11-16.
20. Friedman L, Alder JD, Silverman JA. 2006. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents Chemother 50:2137-2145. http://dx.doi.org/10.1128 /AAC.00039-06.
21. Jones T, Yeaman MR, Sakoulas G, Yang SJ, Proctor RA, Sahl HG, Schrenzel J, Xiong YQ, Bayer AS. 2008. Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob Agents Chemother 52:269-278. http://dx.doi.org/10 .1128/AAC.00719-07.
22. Boyle-Vavra S, Jones M, Gourley BL, Holmes M, Ruf R, Balsam AR, Boulware DR, Kline S, Jawahir S, Devries A, Peterson SN, Daum RS. 2011. Comparative genome sequencing of an isogenic pair of USA800 clinical methicillin-resistant Staphylococcus aureus isolates obtained before and after daptomycin treatment failure. Antimicrob Agents Chemother 55:2018-2025. http://dx.doi.org/10.1128/AAC.01593-10.
23. Yang SJ, Nast CC, Mishra NN, Yeaman MR, Fey PD, Bayer AS. 2010. Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms. Antimicrob Agents Chemother 54:3079-3085. http://dx.doi.org/10.1128/AAC.00122-10.
24. Pillai SK, Gold HS, Sakoulas G, Wennersten C, Moellering RC, Jr, Eliopoulos GM. 2007. Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF. Antimicrob Agents Chemother 51:2223-2225. http://dx .doi.org/10.1128/AAC.00202-07.
25. Mehta S, Cuirolo AX, Plata KB, Riosa S, Silverman JA, Rubio A, Rosato RR, Rosato AE. 2012. VraSR two-component regulatory system contributes to mprF-mediated decreased susceptibility to daptomycin in in vivoselected clinical strains of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 56:92-102. http://dx.doi.org/10.1128/AAC .00432-10.
26. Camargo IL, Neoh HM, Cui L, Hiramatsu K. 2008. Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype. Antimicrob Agents Chemother 52:4289-4299. http://dx.doi.org/10.1128 /AAC.00417-08.
27. Cui L, Isii T, Fukuda M, Ochiai T, Neoh HM, Camargo IL, Watanabe Y, Shoji M, Hishinuma T, Hiramatsu K. 2010. An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus. Antimicrob Agents Chemother 54:5222-5233. http://dx .doi.org/10.1128/AAC.00437-10.
28. Cui L, Tominaga E, Neoh HM, Hiramatsu K. 2006. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 50:1079-1082. http://dx.doi.org/10.1128/AAC.50.3.1079-1082 .2006.
29. Mishra NN, Yang SJ, Sawa A, Rubio A, Nast CC, Yeaman MR, Bayer AS. 2009. Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 53:2312-2318. http://dx.doi.org/10 .1128/AAC.01682-08.
30. Yang SJ, Kreiswirth BN, Sakoulas G, Yeaman MR, Xiong YQ, Sawa A, Bayer AS. 2009. Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. J Infect Dis 200:1916-1920. http://dx.doi .org/10.1086/648473.
31. Yang SJ, Xiong YQ, Dunman PM, Schrenzel J, Francois P, Peschel A, Bayer AS. 2009. Regulation of mprF in daptomycin-nonsusceptible Staphylococcus aureus strains. Antimicrob Agents Chemother 53:2636-2637. http://dx.doi.org/10.1128/AAC.01415-08.
32. Rubio A, Conrad M, Haselbeck RJ, Kedar GC, Brown-Driver V, Finn J, Silverman JA. 2011. Regulation of mprF by antisense RNA restores daptomycin susceptibility to daptomycin-resistant isolates of Staphylococcus aureus. Antimicrob Agents Chemother 55:364-367. http://dx.doi.org/10 .1128/AAC.00429-10.
33. Bertsche U, Weidenmaier C, Kuehner D, Yang SJ, Baur S, Wanner S, François P, Schrenzel J, Yeaman MR, Bayer AS. 2011. Correlation of daptomycin resistance in a clinical Staphylococcus aureus strain with increased cell wall teichoic acid production and D-alanylation. Antimicrob Agents Chemother 55:3922-3928. http://dx.doi.org/10.1128/AAC.01226-10.
34. Mishra NN, McKinnell J, Yeaman MR, Rubio A, Nast CC, Chen L, Kreiswirth BN, Bayer AS. 2011. In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother 55:4012-4018. http://dx.doi.org/10.1128/AAC.00223-11.
35. Fischer A, Yang SJ, Bayer AS, Vaezzadeh AR, Herzig S, Stenz L, Girard M, Sakoulas G, Scherl A, Yeaman MR, Proctor RA, Schrenzel J, François P. 2011. Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approach. J Antimicrob Chemother 66:1696-1711. http://dx .doi.org/10.1093/jac/dkr195.
36. Song Y, Rubio A, Jayaswal RK, Silverman JA, Wilkinson BJ. 2013. Additional routes to Staphylococcus aureus daptomycin resistance as revealed by comparative genome sequencing, transcriptional profiling, and phenotypic studies. PLoS One 8:e58469. http://dx.doi.org/10.1371 /journal.pone.0058469.
37. Patel JB, Jevitt LA, Hageman J, McDonald LC, Tenover FC. 2006. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis 42: 1652-1653. http://dx.doi.org/10.1086/504084.
38. Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC, Jr, Eliopoulos GM. 2006. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 50:1581-1585. http://dx.doi.org/10.1128/AAC.50.4.1581-1585.2006.
39. Lenski RE. 1988. Experimental studies of pleiotropy and epistasis in Escherichia coli 0.1. Variation in competitive fitness among mutants resistant to virus-T4. Evolution 42:425-432.
40. Wichelhaus TA, Böddinghaus B, Besier S, Schäfer V, Brade V, Ludwig A. 2002. Biological cost of rifampin resistance from the perspective of Staphylococcus aureus. Antimicrob Agents Chemother 46:3381-3385. http://dx.doi.org/10.1128/AAC.46.11.3381-3385.2002.
41. Kennedy MC, Emptage MH, Dreyer JL, Beinert H. 1983. The role of iron in the activation-inactivation of aconitase. J Biol Chem 258:11098-11105.
42. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254. http://dx.doi.org/10.1016/0003-2697(76)90527-3.
43. Halouska S, Zhang B, Gaupp R, Lei S, Snell E, Fenton RJ, Barletta RG, Somerville GA, Powers R. 2013. Revisiting protocols for the NMR analysis of bacterial metabolomes. J Integr OMICS 3:120-137. http://dx.doi .org/10.5584/jiomics.v3i2.139.
44. Zhang B, Halouska S, Schiaffo CE, Sadykov MR, Somerville GA, Powers R. 2011. NMR analysis of a stress response metabolic signaling network. J Proteome Res 10:3743-3754. http://dx.doi.org/10.1021/pr200360w.
45. Worley B, Powers R. 2014. MVAPACK: a complete data handling package for NMR metabolomics. ACS Chem Biol 9:1138-1144. http://dx.doi .org/10.1021/cb4008937.
46. Worley B, Powers R. 2014. Simultaneous phase and scatter correction for NMR datasets. Chemometr Intell Lab Syst 131:1-6. http://dx.doi.org/10 .1016/j.chemolab.2013.11.005.
47. De Meyer T, Sinnaeve D, Van Gasse B, Tsiporkova E, Rietzschel ER, De Buyzere ML, Gillebert TC, Bekaert S, Martins JC, Van Criekinge W. 2008. NMR-based characterization of metabolic alterations in hypertension using an adaptive, intelligent binning algorithm. Anal Chem 80: 3783-3790. http://dx.doi.org/10.1021/ac7025964.
48. Worley B, Halouska S, Powers R. 2013. Utilities for quantifying separation in PCA/PLS-DA score plots. Anal Biochem 433:102-104. http://dx .doi.org/10.1016/j.ab.2012.10.011.
49. Werth MT, Halouska S, Shortridge MD, Zhang B, Powers R. 2010. Analysis of metabolomic PCA data using tree diagrams. Anal Biochem 399:58-63. http://dx.doi.org/10.1016/j.ab.2009.12.022.
50. Eriksson L, Trygg J, Wold S. 2008. CV-ANOVA for significance testing of PLS and OPLS® models. J Chemom 22:594-600. http://dx.doi.org/10 .1002/cem.1187.
51. Shao J. 1993. Linear model selection by cross-validation. J Am Stat Assoc 88:486-494. http://dx.doi.org/10.1080/01621459.1993.10476299.
52. Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A. 1995. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J Biomol NMR 6:277-293.
53. Johnson BA. 2004. Using NMRView to visualize and analyze the NMR spectra of macromolecules. Methods Mol Biol 278:313-352.
54. Akiyama K, Chikayama E, Yuasa H, Shimada Y, Tohge T, Shinozaki K, Hirai MY, Sakurai T, Kikuchi J, Saito K. 2008. PRIMe: a web site that assembles tools for metabolomics and transcriptomics. In Silico Biol 8:339-345.
55. Wishart DS, Knox C, Guo AC, Eisner R, Young N, Gautam B, Hau DD, Psychogios N, Dong E, Bouatra S, Mandal R, Sinelnikov I, Xia J, Jia L, Cruz JA, Lim E, Sobsey CA, Shrivastava S, Huang P, Liu P, Fang L, Peng J, Fradette R, Cheng D, Tzur D, Clements M, Lewis A, De Souza A, Zuniga A, Dawe M, Xiong Y, Clive D, Greiner R, Nazyrova A, Shaykhutdinov R, Li L, Vogel HJ, Forsythe I. 2009. HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res 37:D603-D610. http://dx.doi.org/10.1093/nar/gkn810.
56. Ulrich EL, Akutsu H, Doreleijers JF, Harano Y, Ioannidis YE, Lin J, Livny M, Mading S, Maziuk D, Miller Z, Nakatani E, Schulte CF, Tolmie DE, Kent Wenger R, Yao H, Markley JL. 2008. BioMagResBank. Nucleic Acids Res 36:D402-D408.
57. de Jonge BL, Chang YS, Gage D, Tomasz A. 1992. Peptidoglycan composition of a highly methicillin-resistant Staphylococcus aureus strain. The role of penicillin binding protein 2A. J Biol Chem 267:11248-11254.
58. Hutter JL, Bechhoefer J. 1993. Calibration of atomic-force microscope tips. Rev Sci Instrum 64:1868-1873. http://dx.doi.org/10.1063/1.1143970.
59. Nečas D, Klapetek P. 2012. Gwyddion: an open-source software for SPM data analysis. Cent Eur J Physics 10:181-188. http://dx.doi.org/10.2478 /s11534-011-0096-2.
60. Nelson JL, Rice KC, Slater SR, Fox PM, Archer GL, Bayles KW, Fey PD, Kreiswirth BN, Somerville GA. 2007. Vancomycin-intermediate Staphylococcus aureus strains have impaired acetate catabolism: implications for polysaccharide intercellular adhesin synthesis and autolysis. Antimicrob Agents Chemother 51:616-622. http://dx.doi.org/10.1128/AAC.01057-06.
61. Somerville GA, Chaussee MS, Morgan CI, Fitzgerald JR, Dorward DW, Reitzer LJ, Musser JM. 2002. Staphylococcus aureus aconitase inactivation unexpectedly inhibits post-exponential-phase growth and enhances stationary-phase survival. Infect Immun 70:6373-6382. http://dx.doi.org/10 .1128/IAI.70.11.6373-6382.2002.
62. Somerville GA, Saïd-Salim B, Wickman JM, Raffel SJ, Kreiswirth BN, Musser JM. 2003. Correlation of acetate catabolism and growth yield in Staphylococcus aureus: implications for host-pathogen interactions. Infect Immun 71:4724-4732. http://dx.doi.org/10.1128/IAI.71.8.4724-4732 .2003.
63. Gaupp R, Schlag S, Liebeke M, Lalk M, Götz F. 2010. Advantage of up-regulation of succinate dehydrogenase in Staphylococcus aureus biofilm. J Bacteriol 192:2385-2394. http://dx.doi.org/10.1128/JB.01472-09.
64. nd ed. Wiley, New York, NY.
65. Yu H, Yang J. 2001. A direct LDA algorithm for high-dimensional data - with application to face recognition. Pattern Recognit 34:2067-2070. http: //dx.doi.org/10.1016/S0031-3203(00)00162-X.
66. Xu Q-S, Liang Y-Z, Du Y-P. 2004. Monte Carlo cross-validation for selecting a model and estimating the prediction error in multivariate calibration. J Chemom 18:112-120. http://dx.doi.org/10.1002/cem.858.
67. Cramton SE, Gerke C, Schnell NF, Nichols WW, Götz F. 1999. The intercellular adhesion (ica) locus is present in Staphylococcus aureus and is required for biofilm formation. Infect Immun 67:5427-5433.
68. O'Riordan K, Lee JC. 2004. Staphylococcus aureus capsular polysaccharides. Clin Microbiol Rev 17:218-234. http://dx.doi.org/10.1128/CMR.17 .1.218-234.2004.
69. Xia G, Kohler T, Peschel A. 2010. The wall teichoic acid and lipoteichoic acid polymers of Staphylococcus aureus. Int J Med Microbiol 300:148-154. http://dx.doi.org/10.1016/j.ijmm.2009.10.001.
70. Pereira MP, Brown ED. 2004. Bifunctional catalysis by CDP-ribitol synthase: convergent recruitment of reductase and cytidylyltransferase activities in Haemophilus influenzae and Staphylococcus aureus. Biochemistry 43:11802-11812. http://dx.doi.org/10.1021/bi048866v.
71. Ender M, McCallum N, Adhikari R, Berger-Bächi B. 2004. Fitness cost of SCCmec and methicillin resistance levels in Staphylococcus aureus. Antimicrob Agents Chemother 48:2295-2297. http://dx.doi.org/10.1128 /AAC.48.6.2295-2297.2004.
72. Hiramatsu K, Cui L, Kuroda M, Ito T. 2001. The emergence and evolution of methicillin-resistant Staphylococcus aureus. Trends Microbiol 9:486-493. http://dx.doi.org/10.1016/S0966-842X(01)02175-8.
73. Lee SM, Ender M, Adhikari R, Smith JM, Berger-Bächi B, Cook GM. 2007. Fitness cost of staphylococcal cassette chromosome mec in methicillin-resistant Staphylococcus aureus by way of continuous culture. Antimicrob Agents Chemother 51:1497-1499. http://dx.doi.org/10.1128/AAC .01239-06.
74. Hurdle JG, O'Neill AJ, Ingham E, Fishwick C, Chopra I. 2004. Analysis of mupirocin resistance and fitness in Staphylococcus aureus by molecular genetic and structural modeling techniques. Antimicrob Agents Chemother 48:4366-4376. http://dx.doi.org/10.1128/AAC.48.11.4366-4376 .2004.
75. O'Neill AJ, Huovinen T, Fishwick CW, Chopra I. 2006. Molecular genetic and structural modeling studies of Staphylococcus aureus RNA polymerase and the fitness of rifampin resistance genotypes in relation to clinical prevalence. Antimicrob Agents Chemother 50:298-309. http://dx .doi.org/10.1128/AAC.50.1.298-309.2006.
76. Sieradzki K, Leski T, Dick J, Borio L, Tomasz A. 2003. Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for chemotherapy. J Clin Microbiol 41:1687-1693. http://dx.doi.org/10 .1128/JCM.41.4.1687-1693.2003.
77. Graham JE, Wilkinson BJ. 1992. Staphylococcus aureus osmoregulation: roles for choline, glycine betaine, proline, and taurine. J Bacteriol 174: 2711-2716.
78. Miller KJ, Zelt SC, Bae J-H. 1991. Glycine betaine and proline are the principal compatible solutes of Staphylococcus aureus. Curr Microbiol 23: 131-137. http://dx.doi.org/10.1007/BF02091971.
79. Kunin CM, Rudy J. 1991. Effect of NaCl-induced osmotic stress on intracellular concentrations of glycine betaine and potassium in Escherichia coli, Enterococcus faecalis, and staphylococci. J Lab Clin Med 118: 217-224.
80. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak MJ, Talan DA, Chambers HF. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 52:285-292. http://dx.doi.org/10.1093/cid/cir034.
81. Richter SS, Diekema DJ, Heilmann KP, Dohrn CL, Crispell EK, Riahi F, McDanel JS, Satola SW, Doern GV. 2014. Activity of vancomycin, ceftaroline, and mupirocin against Staphylococcus aureus from a 2011 national surveillance study in the United States. Antimicrob Agents Chemother 58:740-745.
82. Bayer AS, Schneider T, Sahl HG. 2013. Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall. Ann N Y Acad Sci 1277:139-158. http://dx.doi.org/10.1111/j.1749-6632 .2012.06819.x.